Cefoperazone Sodium and Sulbactam Sodium for Injection (2:1)

This product has good antibacterial effect on Escherichia coli, Klebsiella, Proteus, Salmonella typhi, Shigella, Citrobacter and other Enterobacteriaceae and Pseudomonas aeruginosa. Haemophilus influenzae, Neisseria gonorrhoeae and Neisseria meningitidis are highly sensitive to this product. This product also has a good effect on all groups of streptococci and pneumococci, and has only a moderate effect on Staphylococcus aureus (methicillin-sensitive strains). Cefoperazone has a good effect on most Gram-positive anaerobes and some Gram-negative anaerobes. Cefoperazone mainly inhibits the synthesis of bacterial cell walls. Sulbactam itself has a weak antibacterial effect and is a competitive, irreversible β-lactamase inhibitor. When used in combination with cefoperazone, it can increase the ability of cefoperazone to resist degradation by multiple β-lactamases, and produce a significant synergistic effect on cefoperazone.

This product is a compound preparation, and its components are: each vial contains 0.5g of cefoperazone sodium calculated as cefoperazone and 0.5g of sulbactam sodium calculated as sulbactam.

This product is white or off-white powder.

This product is used to treat the following infections caused by sensitive bacteria: respiratory tract infections (upper and lower respiratory tract); urinary tract infections (upper and lower urinary tract); peritonitis, cholecystitis, cholangitis and other intra-abdominal infections; sepsis, meningitis; skin and soft tissue infections, eye infections, bone and joint infections; pelvic inflammatory disease, endometritis, gonorrhea and other genital and tract infections; prevention of postoperative infections caused by abdominal, gynecological, cardiovascular, orthopedic and plastic surgery.

1 Adult use: The recommended daily dose of cefoperazone/sulbactam for adults (ratio 1:1) is as follows: Cefoperazone/sulbactam (g) 2.0-4.0 Cefoperazone (g) 1.0-2.0 Sulbactam (g) 1.0-2.0 The above doses are divided into equal parts and administered once every 12 hours. In severe or refractory infections, the daily dose of cefoperazone/sulbactam can be increased to 8 grams (1:1 cefoperazone/sulbactam, i.e. 4 grams of cefoperazone and 4 grams of sulbactam each). If necessary, patients receiving 1:1 cefoperazone/sulbactam treatment can increase the dose of cefoperazone separately. The dose should be divided into equal parts and administered once every 12 hours. The recommended maximum daily dose of sulbactam is

1 Mainly gastrointestinal reactions, such as loose stools or mild diarrhea, nausea, vomiting, etc. 2 Allergic reactions: maculopapular rash, urticaria, eosinophilia, drug fever. These allergic reactions are prone to occur in patients with a history of allergies, especially those allergic to penicillin. 3 Blood system: neutropenia, decreased hemoglobin, thrombocytopenia, hypoprothrombinemia, eosinophilia, etc. 4 Laboratory tests: increased alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase and blood bilirubin, increased urea nitrogen or creatinine, mostly transient. 5 Other reactions: headache, fever, chills, pain at the injection site, phlebitis, bacterial colony imbalance, etc.

Patients who are allergic to this product or cephalosporins are contraindicated.

Precautions for children: This product can be used for children, but no in-depth research has been conducted on the side effects of infants less than 6 months old and premature infants. Precautions for pregnancy and lactation: The concentration of this product in the breast milk of lactating women is very low, but it should still be used with caution during pregnancy and lactation.

1. Combined use with aminoglycoside antibiotics (gentamicin and tobramycin) has a synergistic effect on certain sensitive strains of Enterobacteriaceae and Pseudomonas aeruginosa. However, there are physical incompatibility taboos between this product and aminoglycoside antibiotics, so the two liquids cannot be directly mixed. If combined use is required, the two drugs can be injected intravenously in sequence. Different intravenous infusion tubes should be used for injection, or the previously used intravenous infusion tube should be fully flushed with another approved diluent during the injection interval. In addition, the interval between the administration of the two drugs should be extended as much as possible. 2. When used simultaneously with the following drugs, bleeding may occur: anticoagulant heparin, coumarin or indandione derivatives, thrombolytic drugs, non-steroidal anti-inflammatory analgesics (especially aspirin, diflunisal or other salicylic acid preparations) and sulfinpyrazone, etc. 3. This product is incompatible with compound sodium lactate injection or lidocaine hydrochloride injection. Therefore, the use of this solution during initial dissolution should be avoided, but a two-step dilution method can be used. That is, it is first dissolved with sterile water for injection, and then further diluted with compound sodium lactate injection or lidocaine hydrochloride injection to obtain a mixed solution that can be compatible with each other. 4 It is also incompatible with the following drug injections: doxycycline, meclofenoxate, amarin (Bianmailing), hydroxyzine hydrochloride (Antai Le), procainamide, aminophylline, prochlorperazine, cytochrome C, pentazocine (Zhentongxin), aprotinin, etc.

Sealed, stored in a cool, dark and dry place. Validity period: 24 months

0.75g (C25H27N9O8S20.5g and C8H11NO5S0.25g)

24 months

Kinhoo Pharmaceutical Co., Ltd.

• Founded in:

  2005-04-18

• Address:

  Zhuhai Golden Coast Bio-Industrial Zone

• Tax NO.:

  914404007740042759

• Registered Funds:

  65.6 million yuan

• Website:

  Log in to view

• Email:

  Log in to view